Valneva starts PhII C. diff trial; EC backs Ebola vaccine consortium for GSK candidate;

> Valneva has kicked off a Phase II trial of its Clostridium difficile vaccine. Report

> The European Commission (EC) has put €15.1 million behind a consortium of leading research institutions devoted to advancing development of GlaxoSmithKline's Ebola vaccine candidate. More

> Seattle researchers have discovered a vaccine candidate that they expect to stimulate the production of neutralizing antibodies that defend against infection from a broad spectrum of HIV strains. Release

> The U.S. Patent and Trademark Office has issued key protection for ImmunoCellular Therapeutics' glioblastoma vaccine. Release

And Finally... A mumps outbreak that has so far affected 15 NHL players on 5 teams "could happen anywhere," experts say. More

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.